173 related articles for article (PubMed ID: 17031400)
1. Reduction of mitomycin C is catalysed by human recombinant NRH:quinone oxidoreductase 2 using reduced nicotinamide adenine dinucleotide as an electron donating co-factor.
Jamieson D; Tung AT; Knox RJ; Boddy AV
Br J Cancer; 2006 Nov; 95(9):1229-33. PubMed ID: 17031400
[TBL] [Abstract][Full Text] [Related]
2. NRH:quinone oxidoreductase 2 (NQO2) catalyzes metabolic activation of quinones and anti-tumor drugs.
Celli CM; Tran N; Knox R; Jaiswal AK
Biochem Pharmacol; 2006 Jul; 72(3):366-76. PubMed ID: 16765324
[TBL] [Abstract][Full Text] [Related]
3. Catalytic properties of NAD(P)H:quinone oxidoreductase-2 (NQO2), a dihydronicotinamide riboside dependent oxidoreductase.
Wu K; Knox R; Sun XZ; Joseph P; Jaiswal AK; Zhang D; Deng PS; Chen S
Arch Biochem Biophys; 1997 Nov; 347(2):221-8. PubMed ID: 9367528
[TBL] [Abstract][Full Text] [Related]
4. Reduction and Scavenging of Chemically Reactive Drug Metabolites by NAD(P)H:Quinone Oxidoreductase 1 and NRH:Quinone Oxidoreductase 2 and Variability in Hepatic Concentrations.
den Braver-Sewradj SP; den Braver MW; Toorneman RM; van Leeuwen S; Zhang Y; Dekker SJ; Vermeulen NPE; Commandeur JNM; Vos JC
Chem Res Toxicol; 2018 Feb; 31(2):116-126. PubMed ID: 29281794
[TBL] [Abstract][Full Text] [Related]
5. NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.
Jamieson D; Wilson K; Pridgeon S; Margetts JP; Edmondson RJ; Leung HY; Knox R; Boddy AV
Clin Cancer Res; 2007 Mar; 13(5):1584-90. PubMed ID: 17332305
[TBL] [Abstract][Full Text] [Related]
6. Bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by human NAD(P)H quinone oxidoreductase 2: a novel co-substrate-mediated antitumor prodrug therapy.
Knox RJ; Jenkins TC; Hobbs SM; Chen S; Melton RG; Burke PJ
Cancer Res; 2000 Aug; 60(15):4179-86. PubMed ID: 10945627
[TBL] [Abstract][Full Text] [Related]
7. Evidence for NQO1 and NQO2 catalyzed reduction of ortho- and para-quinone methides.
Kucera HR; Livingstone M; Moscoso CG; Gaikwad NW
Free Radic Res; 2013 Dec; 47(12):1016-26. PubMed ID: 24074361
[TBL] [Abstract][Full Text] [Related]
8. Interactions of the antioxidant enzymes NAD(P)H: Quinone oxidoreductase 1 (NQO1) and NRH: Quinone oxidoreductase 2 (NQO2) with pharmacological agents, endogenous biochemicals and environmental contaminants.
Rashid MH; Babu D; Siraki AG
Chem Biol Interact; 2021 Aug; 345():109574. PubMed ID: 34228969
[TBL] [Abstract][Full Text] [Related]
9. Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H:quinone oxidoreductase gene family. Extensive polymorphism at the NQO2 gene locus on chromosome 6.
Jaiswal AK; Burnett P; Adesnik M; McBride OW
Biochemistry; 1990 Feb; 29(7):1899-906. PubMed ID: 1691923
[TBL] [Abstract][Full Text] [Related]
10. NRH:quinone oxidoreductase 2 and NAD(P)H:quinone oxidoreductase 1 protect tumor suppressor p53 against 20s proteasomal degradation leading to stabilization and activation of p53.
Gong X; Kole L; Iskander K; Jaiswal AK
Cancer Res; 2007 Jun; 67(11):5380-8. PubMed ID: 17545619
[TBL] [Abstract][Full Text] [Related]
11. Evidence for NQO2-mediated reduction of the carcinogenic estrogen ortho-quinones.
Gaikwad NW; Yang L; Rogan EG; Cavalieri EL
Free Radic Biol Med; 2009 Jan; 46(2):253-62. PubMed ID: 18996184
[TBL] [Abstract][Full Text] [Related]
12. Mechanism-based inhibition of quinone reductase 2 (NQO2): selectivity for NQO2 over NQO1 and structural basis for flavoprotein inhibition.
Dufour M; Yan C; Siegel D; Colucci MA; Jenner M; Oldham NJ; Gomez J; Reigan P; Li Y; De Matteis CI; Ross D; Moody CJ
Chembiochem; 2011 May; 12(8):1203-8. PubMed ID: 21506232
[TBL] [Abstract][Full Text] [Related]
13. No associations between Parkinson's disease and polymorphisms of the quinone oxidoreductase (NQO1, NQO2) genes.
Okada S; Farin FM; Stapleton P; Viernes H; Quigley SD; Powers KM; Smith-Weller T; Franklin GM; Longstreth WT; Swanson PD; Checkoway H
Neurosci Lett; 2005 Mar; 375(3):178-80. PubMed ID: 15694256
[TBL] [Abstract][Full Text] [Related]
14. In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2).
Nolan KA; Caraher MC; Humphries MP; Bettley HA; Bryce RA; Stratford IJ
Bioorg Med Chem Lett; 2010 Dec; 20(24):7331-6. PubMed ID: 21074425
[TBL] [Abstract][Full Text] [Related]
15. An Axis between the Long Non-Coding RNA
Nakashima C; Fujiwara-Tani R; Mori S; Kishi S; Ohmori H; Fujii K; Mori T; Miyagawa Y; Yamamoto K; Kirita T; Luo Y; Kuniyasu H
Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142607
[TBL] [Abstract][Full Text] [Related]
16. Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1).
Yan C; Kepa JK; Siegel D; Stratford IJ; Ross D
Mol Pharmacol; 2008 Dec; 74(6):1657-65. PubMed ID: 18794327
[TBL] [Abstract][Full Text] [Related]
17. The reductive metabolism of diaziquone (AZQ) in the S9 fraction of MCF-7 cells: free radical formation and NAD(P)H: quinone-acceptor oxidoreductase (DT-diaphorase) activity.
Fisher GR; Gutierrez PL
Free Radic Biol Med; 1991; 10(6):359-70. PubMed ID: 1654286
[TBL] [Abstract][Full Text] [Related]
18. The role of NAD(P)H:quinone oxidoreductase in mitomycin C- and porfiromycin-resistant HCT 116 human colon-cancer cells.
Pan SS; Akman SA; Forrest GL; Hipsher C; Johnson R
Cancer Chemother Pharmacol; 1992; 31(1):23-31. PubMed ID: 1458556
[TBL] [Abstract][Full Text] [Related]
19. NRH:quinone oxidoreductase2 (NQO2).
Long DJ; Jaiswal AK
Chem Biol Interact; 2000 Dec; 129(1-2):99-112. PubMed ID: 11154737
[TBL] [Abstract][Full Text] [Related]
20. NQO1 and NQO2 regulation of humoral immunity and autoimmunity.
Iskander K; Li J; Han S; Zheng B; Jaiswal AK
J Biol Chem; 2006 Oct; 281(41):30917-24. PubMed ID: 16905546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
